98 filings
Page 2 of 5
8-K
nxiuhdz8 4r3
4 Mar 22
Departure of Directors or Certain Officers
4:42pm
8-K
zz4 spgcsd5o
14 Feb 22
Beyond Air® Reports Financial Results for the Third Quarter of Fiscal Year 2022
8:00am
8-K
id3kh vgd2y4866x
4 Feb 22
Entry into a Material Definitive Agreement
4:35pm
8-K
1y16n
10 Dec 21
Beyond Air® Provides Regulatory Update for LungFit® PH
4:15pm
8-K
czpz06l18 nnj757o2
15 Nov 21
Beyond Air® Reports Financial Results for the Second Quarter of Fiscal Year 2022
4:10pm
8-K
mjp uoeebojrp10xghgl
5 Nov 21
Other Events
8:11am
8-K
qwldkth3gdt6hs
20 Oct 21
Beyond Air® Reports Positive Interim Results for LungFit® GO Pilot Study
8:36am
8-K
dyjewdrd7x6b61aix
27 Sep 21
Beyond Air® Provides Global Regulatory Update for LungFit® PH
4:10pm
8-K
54zkcn2f0 l1md
25 Aug 21
Beyond Air® Announces CFO Transition
5:27pm
8-K
sxnbomhvb0a8e
11 Aug 21
Beyond Air® Reports Financial Results for the First Quarter of Fiscal Year 2022
4:21pm
8-K
ykchux0k8p3lxcnof9xz
16 Jun 21
Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2021
11:52am
8-K
1fer51bbllavimri3
26 May 21
Entry into a Material Definitive Agreement
5:29pm
8-K
b3v62 23diujvrrg98j
13 May 21
Beyond Air® Presents Data in Hospitalized Patients with Viral Lung Infections (including COVID-19) from LungFit® PRO Programs at ATS 2021
8:57am
8-K
8ylmru5m8 l5
9 Mar 21
Departure of Directors or Certain Officers
4:19pm
8-K
5e1tk
16 Feb 21
Other Events
9:08am
8-K
1b4urmtx1
11 Feb 21
Beyond Air® Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Business Update
9:00am
8-K
t5hqtxh
7 Dec 20
Expect to dose first patient in January 2021 and report interim data mid-2021
5:25pm
8-K
gq82r p9qjgojf8
13 Nov 20
Regulation FD Disclosure
4:59pm
8-K
besqovba vn7
12 Nov 20
Beyond Air® Submits Premarket Approval Application to FDA for LungFit™ PH to Treat Persistent Pulmonary Hypertension of the Newborn
6:07am
8-K
jzc28yl q1kcfe
2 Sep 20
Regulation FD Disclosure
4:16pm